




# PHARMACEUTICAL 2021

Imunon Inc.  
Rank 261 of 402





RealRate

# PHARMACEUTICAL 2021

Imunon Inc.  
Rank 261 of 402



The relative strengths and weaknesses of Imunon Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Imunon Inc. compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 91% points. The greatest weakness of Imunon Inc. is the variable Other Liabilities, reducing the Economic Capital Ratio by 64% points.

The company's Economic Capital Ratio, given in the ranking table, is 37%, being 10% points below the market average of 47%.

Input Variable	Value in 1000 USD
Assets, Current	18,825
Cost of Goods Sold	0
Intangible Assets	2,090
Liabilities, Current	6,753
Liabilities, Non-Current	710
Other Assets	16,318
Other Compr. Net Income	-43
Other Expenses	-1,846
Other Liabilities	11,452
Other Net Income	-4,843
Other Revenues	500
Property and Equipment	295
Research and Development	11,345
Selling, General and Administrative Expense	7,642

Output Variable	Value in 1000 USD
Assets	37,527
Liabilities	18,916
Expenses	17,141
Revenues	500
Stockholders Equity	18,611
Net Income	-21,484
Comprehensive Net Income	-21,505
Economic Capital Ratio	37%